Ovarian cancer patient, location shots and leaders available today at CTRC

WHAT: News conference to celebrate an important national designation for the Cancer Therapy & Research Center (CTRC) at The University of Texas Health Science Center at San Antonio

WHEN: 1:30 p.m. today (Tuesday, Aug. 4)

WHERE: CTRC, 4th floor Grossman Building, Mabee Conference Room
7979 Wurzbach Road (at Floyd Curl)

WHO: Glenn Halff, M.D., interim dean, School of Medicine, UT Health Science Center
Tyler Curiel, M.D., M.P.H., executive director, CTRC at the UT Health Science Center
Murray Johnston, Vice Chair, CTRC Board of Directors and a member of the CTRC Foundation Board

PARKING: Enter from Wurzbach. Park in the surface lot in front of the Burton and Miriam Grossman building. Cross the patio to enter on the second floor. Take elevators just inside entrance to the 4th floor. The Mabee conference room is visible from the elevator.

NOTES: A patient with metastatic ovarian cancer who was placed into a clinical research study of a novel type of immunotherapy and whose cancer is now stable will be available to answer questions. A tour afterward will permit photos/video of new radiation equipment and patients receiving infusions in the Phase One chemotherapy suite.

 

 
The Cancer Therapy & Research Center (CTRC) at The University of Texas Health Science Center at San Antonio is one of the nation’s leading academic research and treatment centers, serving more than 4.4 million people in the high-growth corridor of Central and South Texas including Austin, San Antonio, Laredo and the Rio Grande Valley. CTRC is one of a few elite cancer centers in the country to be named a National Cancer Institute (NCI) Designated Cancer Center, and is one of only three in Texas. A world leader in developing new drugs to treat cancer, The CTRC Institute for Drug Development (IDD) is internationally recognized for conducting the largest oncology Phase I clinical drug trials program in the world, and participates in the clinical and/or preclinical development of many of the cancer drugs approved by the U.S. Food & Drug Administration. For more information, visit the Web site at www.ctrc.net.



Share This Article!